Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder

• Conditions: Overactive Bladder

• Registration Number: NCT02335853
• Lead Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Brief Summary

Nerve growth factor (NGF-R) receptors are between the detrusor muscle fibers and can cause afferent signals. Metabolic syndrome and obesity have been advocated to be risk factors for the development of overactive bladder.

Detailed Description

Overactive bladder is a clinical syndrome characterized urgency, frequency and nocturia. Infection or other obvious causes must be excluded. The overactive bladder is loss of inhibition of the detrusor muscle during the filling or emptying of the bladder.

Specific receptors and neurotransmitters have role in development of overactive bladder. These includes adrenergic, cholinergic, non-adrenergic, non-cholinergic receptors and interstitial cells.

Nerve growth factor (NGF-R) receptors are between the detrusor muscle fibers and can cause afferent signals. Metabolic syndrome and obesity have been advocated to be risk factors for the development of overactive bladder. The investigators believe that our findings will shed light on treatment.

Study Timeline

• Status Verified: 2015-01
• Study Start: 2015-01
• Study First Submitted: 2015-01-02
• Study First Submitted QC: 2015-01-09
• Last Update Submitted: 2015-01-09
• Study First Posted: 2015-01-12
• Last Update Posted: 2015-01-12
• Primary Completion: 2015-12
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 90

Inclusion Criteria

• women with urgency, nocturia and frequency
• Abdominal obesity, defined as a waist circumference in men ≥88 cm
• Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides
• Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C
• Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure
• Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose

Exclusion Criteria

• Chronic obstructive pulmonary disease allergy
• Psychiatric disorders
• Urinary tract infection
• Neurological diseases
• Metabolic diseases
• Pure stress or mixed urinary incontinence
• History of pelvic surgery
• Diabetes mellitus

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
nerve growth factor levels	3 months	association between nerve growth factor levels and overactive bladder

Secondary Outcome Measures

Name	Time	Method
urge incontinence	3 months	number of urge incontinence
overactive bladder symptoms	3 months	number of nocturia,urgency,frequency

Trial Locations

Locations (1)

Bakirkoy Dr Sadi Konuk Training and Research Hospital; 🇹🇷 Istanbul, Bakirkoy, Turkey